Femasys Inc (Nasdaq:FEMY), a biomedical innovator focused on addressing unmet needs in women's health, announced on Thursday that it has received Conformité Européene (CE) mark certification for its FemBloc delivery system, a non-surgical approach to permanent birth control for women.
This approval represents a significant milestone in the availability of FemBloc, which offers a minimally invasive, non-surgical alternative to traditional sterilisation methods.
The FemBloc system delivers a proprietary synthetic tissue adhesive to both fallopian tubes, creating non-functional scar tissue that permanently blocks the tubes. Over time, the blended polymer fully degrades.
The approval follows a successful G12 Special MDR Audit for Class III devices, with the European Medical Agency (EMA) expected to complete its review by mid-2025.
According to Femasys, its innovation provides a lower-cost, less risky option for permanent birth control, offering a significant advancement over surgical procedures.
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma